The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 16.25
Bid: 16.00
Ask: 16.50
Change: 0.00 (0.00%)
Spread: 0.50 (3.125%)
Open: 16.25
High: 16.25
Low: 16.25
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK shareholder meetings calendar - next 7 days

Thu, 18th May 2023 15:03

Friday 19 May 
Bank of Georgia Group PLCAGM
Permanent TSB Group Holdings PLCAGM
Sancus Lending Group LtdAGM
Monday 22 May 
Blackrock Latin American Investment Trust PLCAGM
Crossword Cybersecurity PLCAGM
Judges Scientific PLCAGM
Stelrad Group PLCAGM
Venture Life Group PLCAGM
Tuesday 23 May 
888 Holdings PLCAGM
Access Intelligence PLCAGM
Arix Bioscience PLCAGM
Bank of Ireland Group PLCAGM
Big Technologies PLCAGM
Bigblu Broadband PLCAGM
Centamin PLCAGM
CT Private Equity Trust PLCAGM
Empresaria Group PLCAGM
Epwin Group PLCAGM
Forterra PLCAGM
Fresnillo PLCAGM
Fulcrum Utility Services LtdGM re issue of conversion shares
Gresham Technologies PLCAGM
Harworth Group PLCAGM
Hilton Food Group PLCAGM
hVIVO PLCAGM
HydrogenOne Capital Growth PLCAGM
IQ-AI LtdAGM
JTC PLCAGM
K3 Business Technology Group PLCAGM
Pebble Group PLCAGM
Portmeirion Group PLCAGM
PPHE Hotel Group LtdAGM
Restaurant Group PLCAGM
Shell PLCAGM
Sherborne Investors (Guernsey) C LtdAGM
TMT Investments PLCAGM
Triple Point Income VCT PLCAGM
Triple Point Social Housing REIT PLCAGM
Trustpilot Group PLCAGM
Twentyfour Income Fund LtdAGM
Wickes Group PLCAGM
Xeros Technology Group PLCAGM
Wednesday 24 May 
4imprint Group PLCAGM
Adriatic Metals PLCAGM
Arbuthnot Banking Group PLCAGM
Artisanal Spirits Co PLCAGM
Bango PLCAGM
Coca-Cola Europacific Partners PLCAGM
Deliveroo PLCAGM
Deltic Energy PLCAGM
Distribution Finance Capital Holdings PLCAGM
Dunedin Enterprise Investment Trust PLCAGM
ECSC Group PLCCourt and General Meetings re Daisy Corporate Services Trading Ltd takeover
Empiric Student Property PLCAGM
Fidelity Japan Trust PLCAGM
HICL Infrastructure PLCAGM
Horizonte Minerals PLCAGM
Intertek Group PLCAGM
Ithaca Energy PLCAGM
Kelso Group Holdings PLCAGM
Lookers PLCAGM
M&G PLCAGM
Mercantile Investment Trust PLCAGM
Microlise Group PLCAGM
Mortgage Advice Bureau Holdings PLCAGM
National World PLCAGM
Ondine Biomedical IncAGM
Petershill Partners PLCAGM
Playtech PLCAGM
Quarto Group IncAGM
Real Estate Investors PLCAGM
Tullow Oil PLCAGM
US Solar Fund PLCAGM
Zotefoams PLCAGM
Thursday 25 May 
Alliance Pharma PLCAGM
Biome Technologies PLCAGM
Capital & Regional PLCAGM
Destiny Pharma PLCAGM
Ferrexpo PLCAGM
Fevertree Drinks PLCAGM
Headlam Group PLCAGM
Henry Boot PLCAGM
Hill & Smith PLCAGM
LBG Media PLCAGM
Life Science REIT PLCAGM
LSL Property Services PLCAGM
NAHL Group PLCAGM
Petrofac LtdAGM
Pharos Energy PLCAGM
Prudential PLCAGM
Regional REIT LtdAGM
Resolute Mining LtdAGM
RM PLCAGM
S&U PLCAGM
Sabre Insurance Group PLCAGM
Schroder Asian Total Return Investment Co PLCAGM
TBC Bank Group PLCAGM
Vanquis Banking Group PLCAGM
Zinc Media Group PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.